Publication | Closed Access
A cohort study of <i><scp>MFN2</scp></i> mutations and phenotypic spectrums in Charcot–Marie–Tooth disease <scp>2A</scp> patients
45
Citations
23
References
2014
Year
GeneticsGenetic EpidemiologyPhenotypic SpectrumsPathologyDisease Gene IdentificationClinical GeneticsGenetic DiseasesMendelian DisorderNeuropathologyMolecular DiagnosticsCmt FamiliesVariant InterpretationNeurogeneticsPeripheral NeuropathyMolecular NeuroscienceCohort StudyCharcot-marie-tooth Disease 2AMolecular MedicineRare DiseasesMolecular Diagnostic TechniquesNeurodegenerative DiseasesGenetic DisorderPathogenesisMedical GeneticsMedicineLysosomal Storage Disease
Charcot-Marie-Tooth disease 2A (CMT2A) is the most common axonal form of peripheral neuropathy caused by a defect in the mitofusin 2 (MFN2) gene, which encodes an outer mitochondrial membrane GTPase. MFN2 mutations result in a large range of phenotypes. This study analyzed the prevalence of MFN2 mutation in Korean families with their assorted phenotypes (607 CMT families and 160 CMT2 families). Direct sequencing of the MFN2 coding exons or whole-exome sequencing has been applied to identify causative mutations. A total of 21 mutations were found in 36 CMT2 families. Comparative genotype-phenotype correlations impacting severity, onset age, and specific symptoms were assessed. Most mutations were seen in the GTPase domain (∼86%). A deletion mutation found in the transmembrane helices is reported for the first time, as well as five novel mutations at other domains. MFN2 mutations made up 5.9% of total CMT families, whereas 22.9% in CMT2 families, of which 27.8% occurred de novo. Interestingly, patient phenotypes ranged from mild to severe even for the same mutation, suggesting other factors influenced phenotype and penetrance. This CMT2A cohort study will be useful for molecular diagnosis and treatment of axonal neuropathy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1